Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled CSTC-Exosomes for Early Stage COVID-19 Pneumonia
NCT04389385Phase 1Unknown
- Sponsor
- Erciyes University
- Start
- May 2020
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSTC-Exo in COVID-19 pneumonia, sponsored by Erciyes University. Primary endpoints: Adverse reaction (AE) and severe AE (SAE) at 28 days, Efficacy Assessment at 28 days and 1 more. Status: unknown.
02
Drugs
CSTC-Exo
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04389385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04389385.